New INTREPID trial data dispel concerns of radiation-induced microvascular lesions

LONDON — Microvascular changes induced by external-beam X-ray therapy for age-related macular degeneration regressed spontaneously and did not affect vision, according to a presenter here.During a 3-year safety analysis conducted within the INTREPID trial, researchers took X-rays using the IRay Stereotactic Radiotherapy System (Oraya Therapeutics) as an adjunctive to anti-VEGF therapy with Lucentis (ranibizumab, Genentech), showing the potential to reduce the number of injections by 25% at 2 years.